Watchlists Portfolios Alerts Pricing Sign in Get started

Menu

Inhibikase Therapeutics, Inc. IKT

Full chart Compare

Set alert

1.63 USD +0.08 (+5.16%)

At closeNov 11, 2026, 4:00 PM EST

1.63 0.00 0.00%

After hours · Nov 11, 4:00 PM ET

1.56 Day range 1.66

1.40 52-week range 2.61

YTD: -20.49%
1 year: -0.61%

News

1 day ago globenewswire.com Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity WILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel…
4 weeks ago benzinga.com Chardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5 Chardan Capital analyst Andreas Argyrides initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Neutral rating and announces Price Target of $1.5.